Mapmygenome Brings New RT-PCR Based Tuberculosis Diagnostic Kit To India
Jun 12, 2015
3086 Views
Hyderabad & New Delhi, India, June 12, 2015: Mapmygenome India launched SMART™ Tuberculosis, a new RT-PCR based genetic test for detecting and typing Mycobacterium tuberculosis, in India on June 12, 2015. This test kit is now available for healthcare providers and diagnostic labs. This kit is being developed in partnership with Codiagnostics, USA.
Earlier in May 2015, their PCR-based TB in vitro diagnostic kit SPOLIGO™ TB was awarded the CE certification, enabling its utilization in diagnostics.
Ms. Anu Acharya, CEO of Mapmygenome, said, “SMART TB kit along with SPOLIGO TB kit will enable us to fight better against the dreaded tuberculosis. SPOLIGO TB has always been a star product. With SMART TB, we hope to conquer a large segment of the diagnostics market.”
About SMART™ Tuberculosis
SMART™ Tuberculosis and its components are suitable for clinical and diagnostic labs. A complete, ready-to-use master mix is supplied with the kit. Users just have to add the extracted DNA sample to the master mix and run the test. When run according to the instructions, members of the Tuberculosis Complex (M. tuberculosis, M. bovis, M. canetti, M. microti, M. pinnipedii, and M. africanum) are detected through a conserved region in the DNA gene coding for 16s RNA. It is specific for members of the Tuberculosis Complex and does not detect non-tuberculosis Mycobacterium. A human RNase P gene marker serves as an Internal Positive Control (IPC) to monitor the quality of each reaction.
About Mapmygenome
Mapmygenome India offers a variety of services in the domains of personal genomics, molecular diagnostics, DNA forensics, and brain wellness. Their products and services can be purchased from their stores online (www.mapmygenome.in), through their e-commerce partners such as SnapDeal.com or amazon.in, or from their wide network of diagnostics and hospital partners.
As pioneers of personal genomics in India, they created a new market in the country for predictive tests with their flagship brand Genomepatri™ in April 2013. In February 2014, the Government of Karnataka awarded them the Bio Excellence award “Emerging Company of the Year”. In March 2015, they raised a US $ 1.1 million Pre Series A rounding of funding from multiple sources.
Personal genomics products provide insights into the genetic basis of individuals’ health, including traits, lifestyle, drug responses, inherited conditions, and diseases. By combining genetic report and health history with genetic counseling, Mapmygenome provides actionable steps for individuals and their physicians towards a healthier life.
Molecular diagnostics are tests recommended by doctors for cancer, cardiovascular, neuromuscular, and other key conditions. Mapmygenome also offers molecular tests for TB and other infectious diseases that increase accuracy at very low costs. DNA Forensics include maternity, paternity, sibling, and other identification tests. Brain wellness includes a series of assessments for improving emotional and cognitive efficacy, for assessing leadership skills, and more.
For more information, visit www.mapmygenome.in.